Ernexa Therapeutics Inc
ERNA
Ernexa Therapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Cash of 3.0M vs quarterly burn of ~2.4M implies <2 quarters runway without financing. Survival depends on imminent capital raise.[Cash and Equivalents]
- Goodwill of 2.0M is 57% of equity (3.6M) - impairment would eliminate most book value given tangible book is only 1.5M.[Goodwill]
- Gross profit 1Y growth of -99.8% TTM signals near-complete revenue collapse from prior period.[Gross Profit 1Y Growth TTM]
Watch Triggers
- Cash and Equivalents: Falls below 1.5M or financing announced — Sub-1.5M triggers going concern; financing terms dictate dilution magnitude
- Issuance of Capital Stock: Any non-zero value — Signals survival but at cost of shareholder dilution - terms are critical
- Research and Development TTM: Drops below 2M quarterly — R&D cuts signal pipeline deprioritization or wind-down scenario
Bull Case
Minimal debt (0.15 D/E) and low capex (22K TTM) mean any financing proceeds go directly to R&D runway extension.
Market cap of 10.6M with 3.0M cash implies pipeline valued at only 7.6M - asymmetric upside if any program advances.
Bear Case
At -9.4M annual burn with 3.0M cash, company is ~4 months from insolvency absent financing. Dilution or failure near-certain.
Revenue of 1K with -99.8% gross profit decline shows no commercial traction; pure cash consumption with no visibility to profitability.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage ERNA's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
ERNA faces binary outcome: dilutive financing or operational shutdown within 6 months
- Cash burn of 9.4M TTM vs 3.0M cash
- No revenue generation (1K TTM)
- R&D spend of 4.6M TTM unsustainable
Valuation Context
Caveats
Public Strategies Rankings
See how Ernexa Therapeutics Inc ranks across different investment strategies.
Leverage ERNA's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
ERNA Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$10.2M | — | ||
$7.71M | — | ||
0.02 | — | ||
$1,000 | -99.8% | — | |
$57.29 | — | ||
-992,200% | -988802.5% | — | |
-1,834,100% | -1826586.1% | — | |
$-9.44M | — | ||
0.00 | — | ||
Beta 5Y (Monthly) | unknown | — |
ERNA Dividend History
ERNA Stock Splits
ERNA SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/07/25 | 09/30/25 | 10-Q | |
08/13/25 | 06/30/25 | 10-Q | |
05/07/25 | 03/31/25 | 10-Q | |
03/12/25 | 12/31/24 | Unknown | |
11/12/24 | 09/30/24 | 10-Q | |
08/13/24 | 06/30/24 | 10-Q | |
05/14/24 | 03/31/24 | 10-Q | |
03/14/24 | 12/31/23 | 10-K | |
11/13/23 | 09/30/23 | 10-Q | |
08/11/23 | 06/30/23 | 10-Q | |
05/11/23 | 03/31/23 | 10-Q | |
03/20/23 | 12/31/22 | 10-K | |
11/14/22 | 09/30/22 | 10-Q | |
08/11/22 | 06/30/22 | 10-Q | |
07/01/22 | 03/31/22 | 10-Q | |
04/15/22 | 12/31/21 | 10-K | |
11/12/21 | 09/30/21 | 10-Q | |
08/13/21 | 06/30/21 | 10-Q | |
05/17/21 | 03/31/21 | 10-Q | |
07/01/22 | 12/31/20 | 10-K/A | |
11/12/21 | 09/30/20 | 10-Q | |
08/13/21 | 06/30/20 | 10-Q | |
05/17/21 | 03/31/20 | 10-Q |